News

Hospitals that use the 3-dose vaccine would spend approximately 37% more on prophylaxis for hepatitis B.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

The evidence regarding patients with entecavir-treated chronic hepatitis B without maintaining virological response is limited and uncertain.

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Voxelotor has the potential to decrease long-term problems in pediatric sickle cell disease.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

The new PDUFA date for Nefecon will be December 15, 2021.

An expert considers the buildup of cardiovascular and cardiometabolic innovation, and the role of regulatory delays in it.

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.

CDI rates remained down in 2020 despite an increase in antibiotic use during the pandemic.

Anxiety, social support, mother-infant relationship, and infant temperament all improved after a 1-day CBT-based workshop.

Co-infections of HBV and HIV often lead to an increased risk of overall mortality.

How inclisiran, bempedoic acid, and other investigative therapies may contribute to cardiometabolic disease management.

Voxelotor study results show it’s just as effective in children as adults and adolescents.

Dr. Amar Deshpande said more safety studies are needed before examining whether multiple biologics can be used to treat IBD.

A discussion on the winning qualities of the CARDIA study, and why it's also hard to replicate.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

The cardiologist discusses the lagging nature of US health care authorization and recommendation for already proven agents in cardiovascular risk reduction.

Research shows direct associations between unmanaged, severe OSA and cardiovascular event incidence. An expert reviews mechanisms and cross-sectional studies.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

The Tulane Chief of Endocrinology recalls Dr. Frederick Banting's historic discovery in 1921, and how it still impacts diabetes care today.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

A look at how European experts have shaped risk assessment through demographic-centric algorithms.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

An expert weighs in on improving guidelines to reflect optimal real-world care for patients at high risk of cardiovascular events.